Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Plos One|June 14, 2014
Development and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tetheringScott Boitano, Justin Hoffman, Dipti V Tillu, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 8, 2013
Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tetheringAndrea N Flynn, Justin Hoffman, Dipti V Tillu, et al.
British Journal of Pharmacology|July 4, 2015
The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivoScott Boitano, Justin Hoffman, Andrea N Flynn, et al.
Journal of the American Chemical Society|September 1, 2018
Two-Dimensional Halide Perovskites Incorporating Straight Chain Symmetric Diammonium Ions, (NH3C mH2 mNH3)(CH3NH3) n-1Pb nI3 n+1 ( m = 4-9; n = 1-4)Xiaotong Li, Justin Hoffman, Weijun Ke, et al.
Frontiers in Neurology|November 23, 2020
Characteristics and Impact of U.S. Military Blast-Related Mild Traumatic Brain Injury: A Systematic ReviewHelen Phipps, Stefania Mondello, Arlington Wilson, et al.
National Science Review|October 25, 2021
Regulating off-centering distortion maximizes photoluminescence in halide perovskitesXujie Lü, Constantinos Stoumpos, Qingyang Hu, et al.
Advanced Materials (Deerfield Beach, Fla.)|June 7, 2021
Memory Seeds Enable High Structural Phase Purity in 2D Perovskite Films for High-Efficiency DevicesSiraj Sidhik, Wenbin Li, Mohammad H K Samani, et al.
The Oncologist|June 28, 2017
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsSibylle Loibl, Nicholas C Turner, Jungsil Ro, et al.
Oral Oncology|February 11, 2021
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R Adkins, Jin-Ching Lin, Assuntina Sacco, et al.
Pageof 3